Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Nanobiotix ( (NBTX) ) just unveiled an update. On May 17, 2026, Nanobiotix reported that Johnson & Johnson presented Part 1 data from the CONVERGE randomized Phase 2 trial of its nanoradioenhancer JNJ-1900 (NBTXR3) in patients with stage 3 inoperable non-small cell lung cancer at the ESTRO 2026 meeting. Early results from seven patients showed that intratumoral or intranodal injection of JNJ-1900 combined with concurrent chemoradiotherapy and durvalumab was feasible and appeared safe, with an overall response rate of 85.7%, a complete response rate of 57.1%, a disease control rate of 100%, and no progressive disease observed. These initial outcomes suggest deeper and potentially more durable responses than typically seen with current standard-of-care chemoradiation with or without durvalumab, where complete responses are usually below 5%. The data strengthen Nanobiotix’s strategic positioning around NBTXR3 as a potentially first-in-class, scalable radioenhancer across solid tumors, complementing its ongoing Phase 3 NANORAY-312 head and neck cancer program and its global co-development and commercialization alliance with Johnson & Johnson. The most recent analyst rating on (NBTX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page. Spark’s Take on NBTX Stock According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral. The score is primarily constrained by weak financial fundamentals (ongoing losses, cash burn, and balance-sheet pressure including negative equity and higher leverage). Offsetting this are strong technical momentum (though extended) and a constructive earnings-call outlook emphasizing improved runway and multiple clinical catalysts, while valuation support is limited given negative earnings and no dividend. To see Spark’s full report on NBTX stock, click here. More about Nanobiotix Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris and listed on Euronext Paris and Nasdaq, developing physics-based nanotherapeutics to improve cancer treatment. Its lead product candidate, JNJ-1900 (NBTXR3), is a hafnium oxide nanoparticle radioenhancer designed for one-time intratumoral injection and activation by radiotherapy, with a development focus on solid tumors such as head and neck cancers and partnerships including Janssen and MD Anderson. Average Trading Volume: 75,328 Technical Sentiment Signal: Buy Current Market Cap: $2.46B For a thorough assessment of NBTX stock, go to TipRanks’ Stock Analysis page.